Reduction of plasma fibrinogen, immunoglobulin G, and immunoglobulin M concentrations by immunoadsorption therapy with tryptophan and phenylalanine adsorbents.
Immunoadsorption (IA) therapy with tryptophan (TR-350) or phenylalanine (PH-350) adsorbents has been used to reduce the concentration of serum antibodies in human lymphocyte antigen (HLA)-immunized patients. Other forms of plasma purification have been reported to reduce the level of fibrinogen, which affects the blood properties. In this study we investigated the effects of IA therapy using both adsorbents on plasma fibrinogen and immunoglobulins G and M in 13 patients (8 patients were treated with TR-350, and 5 patients were treated with PH-350). During each session I plasma volume (2.8 +/- 0.4 L of plasma) was processed through the immunocolumn and then returned to the patient together with the blood cells. Compared with the pretreatment values, the plasma fibrinogen, IgG, and IgM concentrations were significantly reduced after IA therapy (p < 0.01 for TR-350; p < 0.04 for PH-350). There was a positive correlation between the degree of reduction of plasma proteins and the number of IA treatments given. A nonparametric test (Wilcoxon's signed-rank test or the Mann-Whitney test) was used for statistical analysis. We conclude from our study that IA therapy effectively lowers the plasma levels of fibrinogen, IgG, and IgM and thus can be considered a valuable alternative to other blood purification methods.
Fadul
J E
JE
Department of Medicine, University Hospital, Uppsala, Sweden.
Danielson
B G
BG
Wikström
B
B
D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000032:analysis / Q000302:isolation & purification; D005260:Female; D005340:Fibrinogen / Q000302:isolation & purification / Q000378:metabolism; D006680:HLA Antigens / Q000009:adverse effects / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000302:isolation & purification; D007075:Immunoglobulin M / Q000097:blood / Q000302:isolation & purification; D007164:Immunosorbents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010649:Phenylalanine / Q000627:therapeutic use*; D006435:Renal Dialysis; D014364:Tryptophan / Q000627:therapeutic use*
D001798:Blood Proteins; D006680:HLA Antigens; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007164:Immunosorbents; D010649:Phenylalanine; D014364:Tryptophan; D005340:Fibrinogen